L3VLUP
ProSign in

BDTX · ARGX in the 13F filings

Two to four stocks side by side among the 95 tracked managers: who lists them, how that has moved, who bought and sold in a quarter, and which managers hold more than one.

BDTXARGX
Quarter
Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023

Holders over time

Tracked managers listing each stock every quarter, at least, or their combined reported value. A gap is a quarter in which no tracked manager listed it. Click a quarter to compare there.
  • BDTX
  • ARGX
0102030202120222023202420252026
Holders and value by quarter
QuarterBDTXARGX
Q3 20201 holders, $16m8 holders, $3.6bn
Q4 20203 holders, $37m7 holders, $4.1bn
Q1 20211 holders, $1.6m8 holders, $4.1bn
Q2 20212 holders, $2.6m9 holders, $4.6bn
Q3 20211 holders, $862k8 holders, $4.5bn
Q4 2021none listed holders, n.a.9 holders, $5.3bn
Q1 2022none listed holders, n.a.8 holders, $5.3bn
Q2 2022none listed holders, n.a.13 holders, $6.5bn
Q3 2022none listed holders, n.a.14 holders, $5.3bn
Q4 2022none listed holders, n.a.13 holders, $5.5bn
Q1 2023none listed holders, n.a.13 holders, $5.9bn
Q2 20231 holders, $252k18 holders, $6.6bn
Q3 20232 holders, $5.0m21 holders, $8.7bn
Q4 20231 holders, $4.4m17 holders, $6.3bn
Q1 2024none listed holders, n.a.13 holders, $6.8bn
Q2 2024none listed holders, n.a.14 holders, $7.9bn
Q3 2024none listed holders, n.a.13 holders, $10.7bn
Q4 2024none listed holders, n.a.14 holders, $12.3bn
Q1 2025none listed holders, n.a.17 holders, $11.8bn
Q2 2025none listed holders, n.a.18 holders, $10.8bn
Q3 2025none listed holders, n.a.16 holders, $13.8bn
Q4 20251 holders, $1.0m16 holders, $14.8bn
Q1 2026none listed holders, n.a.11 holders, $12.3bn
Q2 2026none listed holders, n.a.14 holders, $15.0bn
BDTX

Black Diamond Therapeutics Inc

Holders
0
Reported value
$0
Buyers
9
Sellers
11

Breadth -2 among 91 comparable managers.

Pharmaceuticals and biotechnologyBiological productsHealthcare: biopharma and medtech · L3VLUP
ARGX

Argenx Se

Holders
14
Reported value
$15.0bn
Buyers
16
Sellers
15

Breadth +1 among 91 comparable managers.

Pharmaceuticals and biotechnologyBiological productsHealthcare: biopharma and medtech · L3VLUP

Who holds both, Q2 2026

Among the 14 tracked managers listing any of them. "Only" is about listed positions: a manager may hold the other below its listed range.

Both (0)

No tracked manager lists every one of them.

Only BDTX (0)

None.

Only ARGX (14)

AllianceBernstein LP, Artisan Partners LP, Baillie Gifford & Co, Capital Research Global Investors, Capital World Investors, Fidelity (FMR LLC), Invesco Ltd, Janus Henderson Group Ltd, Squarepoint Ops LLC, T. Rowe Price Associates Inc, Two Sigma Investments LP, Voloridge Investment Management LLC, Wellington Management Group LLP, Woodline Partners LP

How much of the picture this is

A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. Buyers and sellers count comparable managers (those that filed both quarters) by shares, so a rise in value with no rise in shares is the price. Large books are listed to their largest positions. These are 95 tracked managers, not the institutional market.

Back to the 13F Explorer →